Vietnam Patent System

Vietnam's pharmaceutical IP landscape is shaped by its CPTPP obligations, its status as a middle-income country with significant public health needs, and the 2022 IP Law reform implementing pharmaceutical patent linkage. Key aspects: (1) Pre-2022 situation: before the 2022 IP Law amendment, Vietnam had limited pharmaceutical patent linkage. Generic drug applicants could obtain marketing authorization from DAV without notification to originator patent holders. This led to generic market entry that patent holders considered premature; (2) Post-2022 pharmaceutical linkage: the 2022 IP Law amendment (implementing CPTPP Art. 18.53) requires DAV to notify patent holders when a generic application references a patented drug — patent holders can request DAV to delay generic approval while the patent dispute is resolved in Vietnamese courts or administrative proceedings. This is a significant pro-originator change; (3) Compulsory licensing: Vietnam has compulsory licensing provisions under Art. 147 IP Law for national defense, public health emergencies, and non-working. Vietnam invoked compulsory licensing for HIV/AIDS antiretroviral drugs in 2004–2005 (before CPTPP; consistent with Doha Declaration) — similar to Indonesia but at a smaller scale; (4) SPC equivalent: Vietnam does not have a supplementary protection certificate (SPC) system equivalent to the EU SPC Regulation. Patents expire at their 20-year term without extension for regulatory approval delays — NOIP's patent term adjustment provisions under the 2022 IP Law amendment address examination delays but not regulatory approval delays; (5) Generic pharma industry: Vietnam has a significant domestic generic pharmaceutical manufacturing sector (Dược Hậu Giang, Traphaco, Imexpharm, OPV). Generic manufacturers have opposed strong pharmaceutical patent linkage, creating political tensions in the CPTPP implementation process.

Vietnam's technology sector has grown dramatically — Hanoi and Ho Chi Minh City have active startup ecosystems, and Vietnam is investing in becoming a technology hub beyond pure manufacturing. Key aspects: (1) Foreign tech manufacturing IP: Intel Products Vietnam (Ho Chi Minh City — assembles and tests Intel processors; Intel's IP is protected primarily by US/PCT patents, not Vietnamese patents); LG Electronics Vietnam (Hai Phong — TV, home appliances; Korean and PCT patents); Canon Vietnam (Hanoi — laser printer manufacturing); Foxconn Vietnam (Bắc Giang — Apple iPhone assembly; Foxconn's own patents primarily in Taiwan and US); (2) Vietnamese technology companies: VinGroup/VinFast (Hanoi — conglomerate with automotive [EV manufacturing launched 2022, Nasdaq listing 2023], real estate, technology; VinFast holds patents in EV design and components, filed both at NOIP and via PCT); VNPT (state-owned telecom — holds Vietnamese patents in network infrastructure); Viettel (military-owned telecom — active in 5G research and holds Vietnamese and international patents; expanding to African and Asian markets); (3) Software patents at NOIP: Vietnamese IP Law excludes 'mathematical methods, mental acts and computer programs' as such from patentability (consistent with TRIPS Art. 27(2)). However, software with a technical character — computer-implemented inventions producing a technical effect — can be patented. NOIP examination of software claims follows broad EPO-like principles but with limited specialized examiner resources for software-heavy applications; (4) Vietnam's digital economy: by 2023, Vietnam's digital economy reached approximately $30 billion GMV (gross merchandise value) — e-commerce, ride-hailing, fintech. Companies like Grab (Singapore-based but Vietnam is major market), VNPay (fintech), and Momo (e-wallet) are active in the space; patent protection for digital innovations is primarily via Singapore filings with PCT national phase in key markets.

Vietnam's Law 07/2022/QH15 (effective January 1, 2023) was the most significant update to Vietnam's IP Law since its enactment in 2005. For patents specifically, the key changes were: (1) Pharmaceutical patent linkage (CPTPP Art. 18.53): This is the most commercially important patent change. Under the 2022 amendment, when a generic drug manufacturer applies to the Drug Administration of Vietnam (DAV) for marketing authorization for a drug that may be covered by a patent, DAV must notify the patent holder. The patent holder can then request that DAV delay issuance of the generic marketing authorization while the patent dispute is resolved through administrative or court proceedings. Previously, generic approvals could proceed without this notification mechanism. This is a significant pro-originator change that will affect generic drug market entry timelines in Vietnam; (2) Patent term adjustment for examination delays (CPTPP Art. 18.46): Vietnam introduced provisions to adjust (extend) patent terms to compensate for unreasonable delays in NOIP's examination process. If NOIP takes longer than a specified period to process a patent application, the patent holder may be entitled to term adjustment — additional time at the end of the 20-year term to compensate for the examination delay. This concept is similar to the US Patent Term Adjustment (PTA) under 35 U.S.C. § 154(b); (3) Genetic resources and traditional knowledge: applicants must disclose the source of genetic resources and traditional knowledge used in inventions — consistent with the Nagoya Protocol; (4) Enhanced border measures: customs authorities received expanded powers to seize IP-infringing goods at Vietnamese borders and ports under updated customs and IP law provisions; (5) UPOV 1991 implementation: Vietnam's accession to UPOV 1991 (required under CPTPP) changed how plant varieties are protected — UPOV 1991 provides stronger breeders' rights than UPOV 1978, which Vietnam previously applied.

Samsung Electronics' massive manufacturing presence in Vietnam — over $20 billion invested, 50%+ of Samsung's global smartphone production — has complex implications for patent strategy: (1) Core technology protection is NOT through Vietnamese patents: Samsung's foundational smartphone technology (Exynos/Snapdragon processor design, OLED display technology, camera systems, software) is protected primarily through Samsung's Korean patents (KIPO), US patents (USPTO), Chinese patents (CNIPA), and European patents (EPO). Samsung does not rely on NOIP Vietnamese patents to protect its core manufacturing technology in Vietnam — the scale of production in Vietnam is enabled by Samsung's global patent fortress; (2) Local supplier ecosystem IP: Samsung's Vietnam operations have created a supplier ecosystem of hundreds of Vietnamese and Korean companies manufacturing components in Vietnam. Process innovations developed by these suppliers — production line adaptations, local material sourcing solutions, logistics optimizations — may generate patentable inventions that are worth capturing through NOIP filings for the Vietnamese market; (3) Competition from Chinese electronics manufacturers: as Chinese electronics brands (Xiaomi, Oppo, Vivo) seek to access Vietnamese consumers, Samsung (already manufacturing in Vietnam) faces competition from companies who also manufacture in Vietnam. Patent enforcement at NOIP for locally-relevant innovations becomes part of competitive positioning; (4) IP enforcement requirements for FDI: Vietnam's CPTPP commitments and IP law reforms were partly driven by the need to attract and retain quality FDI like Samsung. Samsung's continued expansion in Vietnam (including new investments in semiconductor packaging/testing) requires that Vietnam provide credible IP protection — the 2022 IP Law reform reflects this dynamic; (5) For other companies considering Vietnam investment: Samsung's model shows that Vietnam can host high-value manufacturing operations with IP protection flowing primarily from global patent portfolios, not Vietnamese national patents. NOIP filings should be selective — targeting innovations with significant Vietnam-market exposure.

A Vietnamese utility solution (giải pháp hữu ích) under Article 93.3 of the IP Law 2005 provides 10 years of protection for inventions that have novelty and are capable of industrial application, but do not meet the full inventive step standard required for invention patents. Key features: (1) Inventive step threshold: utility solutions require that the invention is new and capable of industrial application — there is no inventive step requirement (or a significantly reduced one). This means incremental improvements, minor adaptations, and straightforward innovations that would fail the inventive step test for an invention patent can qualify as utility solutions; (2) What can be covered: utility solutions cover devices, products, and processes (like invention patents). Unlike some countries' utility models that exclude processes, Vietnamese utility solutions can protect both products and methods; (3) Prosecution speed: utility solution applications at NOIP are typically processed in 1–2 years compared to 3–5 years for invention patents. This speed advantage is commercially significant; (4) No examination for novelty by NOIP: some sources suggest Vietnamese utility solutions were registered without full substantive examination historically — the 2005 IP Law and subsequent amendments have clarified examination requirements. NOIP conducts a substantive examination for novelty and industrial applicability; (5) 10-year term: utility solutions cannot be extended beyond 10 years. For products with shorter commercial life cycles — agricultural equipment, construction materials, industrial tools, food processing equipment — 10 years is often sufficient; (6) Who benefits: Vietnamese utility solutions are particularly useful for Vietnamese SMEs, local manufacturers, and foreign companies with Vietnam-specific innovations where rapid protection is needed. The lower cost and faster prosecution compared to invention patents make utility solutions an efficient first-line protection tool for the Vietnamese market.

Vietnam has a limited grace period under Article 60.3 of the IP Law 2005, but it is significantly narrower than the US AIA grace period and is often misunderstood. The Vietnamese grace period: (1) Scope: disclosures of the invention at a recognized scientific conference or national or international exhibition within 6 months before the Vietnamese patent application filing date do NOT destroy novelty for Vietnamese purposes. This protects applicants who first disclosed at an official scientific conference or recognized exhibition; (2) What is NOT covered: general publications (journal articles, preprint servers), public demonstrations at trade shows or commercial events that are not specifically 'recognized' by the Vietnamese government, product launches, press releases, social media publications, or any other public disclosure not falling within the specific 'scientific conference or recognized exhibition' category. This is dramatically narrower than the US AIA § 102(b)(1) grace period, which covers ANY public disclosure by the applicant or inventor, regardless of form; (3) 6-month window: the Vietnamese grace period is 6 months, shorter than the US 12-month window; (4) Practical implication: Vietnamese applicants should NOT rely on the grace period for most commercial disclosures. A product launch, trade show demonstration, or journal publication before a patent filing date creates prior art that destroys Vietnamese patent novelty, regardless of whether it occurred within 6 months. File the patent application before any public disclosure; (5) EPC/EU comparison: EPC countries have no general grace period (Art. 54 EPC strict absolute novelty, with narrow Art. 55 exceptions similar to Vietnam's conference/exhibition exception). Vietnam's grace period is roughly equivalent in scope to EPC Art. 55 — both narrow exceptions, not general inventor grace periods like the US AIA.

The Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP, which Vietnam joined; the US withdrew from the predecessor TPP in 2017) contains extensive IP obligations in Chapter 18 that required significant Vietnamese IP law reform, implemented primarily through the 2022 IP Law Amendment (Law 07/2022/QH15, effective January 1, 2023). Key CPTPP obligations affecting Vietnamese patent law: (1) Pharmaceutical patent linkage (CPTPP Art. 18.53): drug regulatory authorities must implement a patent linkage mechanism — notifying patent holders of generic applications for patented drugs and providing a mechanism to delay generic approval during patent disputes. Implemented in Vietnam through the 2022 IP Law amendment provisions affecting the Drug Administration of Vietnam (DAV); (2) Patent term adjustment (CPTPP Art. 18.46): parties must provide patent term adjustment for unreasonable examination delays or regulatory approval delays. Vietnam implemented PTA for examination delays in the 2022 amendment; (3) UPOV 1991 (CPTPP Art. 18.69): Vietnam was required to accede to the International Union for the Protection of New Varieties of Plants (UPOV) 1991 Convention, upgrading from UPOV 1978. UPOV 1991 provides stronger plant breeder rights including protection extending to harvest material and certain derived products; (4) Data protection (CPTPP Art. 18.50): protection of undisclosed test data submitted to regulatory authorities for marketing approval; minimum periods for data exclusivity for new pharmaceutical products and agricultural chemical products; (5) Enforcement and border measures (CPTPP Art. 18.77–18.82): enhanced civil and criminal enforcement procedures, including ex officio border measures allowing customs to seize suspected counterfeit goods without rights holder complaint; (6) Genetic resources/traditional knowledge: disclosure requirements for patent applicants concerning genetic resources and traditional knowledge used in inventions.